Neurocrine Biosciences (NBIX) EBIT Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | -80.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.05% |
| Mar 31, 2026 | 719.49% |
| Dec 31, 2025 | 48.52% |
| Sep 30, 2025 | 30.03% |
| Jun 30, 2025 | 0.14% |
| Mar 31, 2025 | -76.23% |
| Dec 31, 2024 | -5.52% |
| Sep 30, 2024 | 30.17% |
| Jun 30, 2024 | 97.55% |
| Mar 31, 2024 | 186.95% |
| Dec 31, 2023 | 45.36% |
| Sep 30, 2023 | 60.82% |
| Jun 30, 2023 | 34.55% |
| Mar 31, 2023 | -3,783.87% |
| Dec 31, 2022 | 384.85% |
| Sep 30, 2022 | 97.30% |
| Jun 30, 2022 | -12.90% |
| Mar 31, 2022 | -90.16% |
| Dec 31, 2021 | -150.56% |
| Sep 30, 2021 | 200.45% |